Home > Press > Nanomix Signs Exclusive Glucose Detection Licensing Agreement With MysticMD
Nanomix Inc., a leading electronic detection company commercializing high-value diagnostic and monitoring applications, today announced an exclusive licensing agreement with MysticMD Inc., a provider of proprietary nano-coatings. Per this agreement, MysticMD will provide Nanomix with intellectual property related to the use of nano-ink for glucose test strip technology. This builds upon earlier work between the two organizations to optimize the technology and explore partnering opportunities.
Nanomix Signs Exclusive Glucose Detection Licensing Agreement With MysticMD
EMERYVILLE, CA | Posted on November 5th, 2007
David Macdonald, Nanomix CEO, said, "We are pleased to have partnered with MysticMD, and believe that our collaboration will create better performing glucose test strips at a lower cost."
Heidi Douglas, co-founder and CEO of MysticMD, said, "We are excited to be working with Nanomix, as they are uniquely positioned to make best use of this IP in product development. With Nanomix' expertise in the area of detection devices, we feel confident that this partnership will enable us to bring this technology to market quickly and effectively through broader collaborations with market leaders."
About Nanomix Inc.
Nanomix is a leading electronic detection company launching detection devices based on Sensation™ technology. These scaleable devices use ultra-sensitive carbon nanotube detection elements combined with proprietary chemistries. They can be deployed across high value respiratory and biomarker detection applications where low power consumption, small size, and ultra-sensitivity offer significant performance advantages and enable unprecedented access to critical information. For additional information, please visit www.nano.com.
MysticMD is an advanced materials company developing proprietary coating solutions using hybrid formulations of carbon nanotubes alloyed with traditional materials and other nano particles to solve real world problems. They are developing an intellectual property portfolio focused on dramatically improving their partners' products in key high value, high opportunity commercial applications. For more information, please visit http://www.mysticmd.com .
For more information, please click here
Copyright © Marketwire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014
QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014
Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014
harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014